New subgroup analysis from STRATUM study shows that individuals with an inadequate response, contraindication, or intolerance to steroids were 3.5 times more likely to achieve IGA Success with ZORYVE foam than an identical vehicleZORYVE foam provided rapid and significant improvement in quality of life scores in patients 17 years and olderData presented at the 2024 Winter Clinical Dermatology Conference - Hawaii WESTLAKE VILLAGE, Calif., Jan.

来自STREAM研究的新亚组分析表明，反应不足，禁忌症，使用ZORYVE泡沫获得IGA成功的可能性比使用相同的载体ZORYVE泡沫获得IGA成功的可能性高3.5倍。ZORYVE泡沫为17岁及以上患者的生活质量评分提供了快速而显着的改善。2024年冬季临床皮肤病学会议-夏威夷西湖村，加利福尼亚州，1月。

14, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced a new subgroup analysis highlighting that adults and adolescents with seborrheic dermatitis who are contraindicated, intolerant, or unresponsive to topical steroids were 3.5 times more likely to achieve IGA Success with ZORYVE® (roflumilast) topical foam, 0.3%, compared to vehicle (78.8% ZORYVE foam; 48.3% vehicle; p<0.001)i.

142024年（环球通讯社）--Arcutis Biotherapeutics，Inc.（纳斯达克：ARQT），一家商业阶段的生物制药公司，专注于在免疫皮肤病学领域开发有意义的创新，今天宣布了一项新的亚组分析，强调成人和青少年脂溢性皮炎患者禁忌，不耐受，与载体（78.8%ZORYVE泡沫；48.3%载体；p＜0.001）i相比，ZORYVE®（罗氟司特）局部泡沫（0.3%）获得IGA成功的可能性是对局部类固醇无反应的3.5倍。

ZORYVE foam is a once-daily steroid-free topical for use in all skin and hair types that effectively clears and controls seborrheic dermatitis. Data were presented at the 2024 Winter Clinical Dermatology Conference – Hawaii held January 12-17, 2024, in Honolulu. Treatment with ZORYVE foam significantly increased the odds of achieving a meaningful improvement in quality of life at Weeks 2, 4, and 8, compared to vehicle as measured by the Dermatology Life Quality Index (DLQI) (odds ratio (OR) 6:97; 95% confidence interval (CI) 3.97, 12.24; p<0.001).

ZORYVE泡沫是一种每日一次的无类固醇外用产品，适用于所有皮肤和头发类型，可有效清除和控制脂溢性皮炎。2024年1月12日至17日在夏威夷檀香山举行的2024年冬季临床皮肤病会议上提供了数据。与通过皮肤病生活质量指数（DLQI）测量的载体相比，用ZORYVE泡沫治疗显着增加了在第2,4和8周实现有意义的生活质量改善的几率（优势比（OR）6:97；95%置信区间（CI）3.97，12.24；p＜0.001）。

DLQI was measured in patients 17 years of age and older. 72.5% of individuals achieved a minimally important differenceii in DLQI score as early as 2 weeks, increasing to 86.6% at the end of the study, Week 8 (compared to 28.1% p=0.001 and 53.6% p=0.001 for vehicle.

在17岁及以上的患者中测量DLQI。72.5%的个体早在2周时就在DLQI评分中取得了最小的重要差异，在研究结束时，第8周增加到86.6%（相比之下，车辆为28.1%p=0.001和53.6%p=0.001）。